Soligenix Q2 2026: Going Concern Warning, Nasdaq Delisting Risk, and Heavy ATM Dilution
SNGX sits 39% above its 52-week low of $0.28.
Summary
Soligenix's Q2 2026 10-Q reveals a going concern warning, Nasdaq delisting risk, and massive ATM-driven dilution — shares outstanding more than doubled in six months. The company terminated its lead drug program and has limited funding options.
Key Events · Earnings and Guidance · SNGX
-
Going Concern Warning
Management expresses substantial doubt about the company's ability to continue as a going concern, citing the need for additional capital and lack of committed funding beyond the ATM facility.
-
Nasdaq Delisting Risk
Received a bid price deficiency notice on June 10, 2026; must regain compliance by December 7, 2026. Also at risk of violating the $5M minimum market value of listed securities rule, which could trigger immediate suspension.
-
Lead Program Terminated
The HyBryte™ Phase 3 FLASH2 trial was halted for futility in April 2026, and the Board terminated the entire program in June 2026, eliminating the company's most advanced asset.
-
Massive ATM Dilution
Sold 11.5 million shares via ATM in H1 2026, raising $6.0 million at a weighted average price of $0.54 — more than doubling shares outstanding from 10.1 million to 21.6 million.
Analysis · SNGX · Life Sciences
Soligenix's Q2 2026 10-Q, filed as part of this prospectus supplement, reveals a going concern warning, a Nasdaq delisting notice, and the sale of 11.5 million shares via its ATM program in the first half of 2026 — more than doubling the share count. The company terminated its lead drug program, HyBryte, after a futility halt, and now relies entirely on dilutive ATM sales to fund operations. With only $2.4 million remaining on the ATM and a reverse stock split vote pending, the survival path is narrow and highly dilutive.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 40.2% of the 326 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.33%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNGX was trading at $0.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.5M. The 52-week trading range was $0.28 to $6.23. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.